SLC5A2 and obesity due to melanocortin 4 receptor deficiency: Subgroup analyses based on baseline BMI showed that SGLT-2 inhibitors showed a significant reduction in SAT only in the obesity group (SMD = − 1.47; 95% CI [− 2.68, − 0.26]; I2 = 95%; p = 0.02; Fig. 6B).